Q3 EPS Forecast for Rhythm Pharmaceuticals Cut by Analyst

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright cut their Q3 2027 earnings estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.33 per share for the quarter, down from their prior estimate of $0.42. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

A number of other research firms also recently commented on RYTM. Citizens Jmp dropped their price objective on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating on the stock in a research note on Tuesday. Needham & Company LLC decreased their target price on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a research note on Tuesday. Stifel Nicolaus set a $131.00 target price on Rhythm Pharmaceuticals in a report on Thursday, February 26th. Telsey Advisory Group set a $143.00 price target on shares of Rhythm Pharmaceuticals in a research report on Thursday, March 12th. Finally, Zacks Research raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $131.13.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM opened at $87.45 on Thursday. The stock has a fifty day moving average price of $99.04 and a two-hundred day moving average price of $102.49. The firm has a market cap of $5.97 billion, a P/E ratio of -28.12 and a beta of 2.06. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. During the same quarter last year, the business earned ($0.72) earnings per share. The business’s revenue for the quarter was up 36.9% on a year-over-year basis.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 148.2% in the first quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock worth $2,085,000 after buying an additional 23,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Rhythm Pharmaceuticals by 6.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock valued at $1,874,000 after acquiring an additional 2,126 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Rhythm Pharmaceuticals by 25.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 184,109 shares of the company’s stock valued at $11,634,000 after acquiring an additional 37,524 shares in the last quarter. Savant Capital LLC acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter worth approximately $277,000. Finally, PNC Financial Services Group Inc. boosted its stake in Rhythm Pharmaceuticals by 22.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,543 shares of the company’s stock worth $350,000 after purchasing an additional 1,025 shares during the period.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at $11,190,445.12. The trade was a 3.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. This trade represents a 97.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 27,267 shares of company stock valued at $2,719,955. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approved IMCIVREE (setmelanotide) for acquired hypothalamic obesity — the first and only therapy for this rare condition, expanding the label and potential patient population, which materially strengthens Rhythm’s commercial runway. Read More.
• Positive Sentiment: Rhythm named PANTHERx® Rare as the exclusive U.S. specialty pharmacy partner for the expanded IMCIVREE indication — this should improve patient access, distribution scale and support launch execution. Read More.
• Neutral Sentiment: Some brokers still assign above-current price targets (one report references a $133.19 consensus PT from select brokers), indicating divergent views on upside even after recent weakness. Read More.
• Neutral Sentiment: Investor/earnings-call coverage and transcripts are circulating (discussing the FDA approval and commercialization plans), useful for modeling uptake but not a direct catalyst on their own. Read More.
• Negative Sentiment: HC Wainwright reduced EPS forecasts across multiple quarters and cut its FY2027 outlook and price target (now $100) — the cuts lower near-term earnings expectations and likely contributed to selling pressure despite the firm maintaining a Buy rating. Read More.
• Negative Sentiment: Multiple brokers published pessimistic forecasts or lowered expectations (Bank of America, RBC, Needham, Citizens JMP), creating additional downward pressure and a wider dispersion of analyst views. Read More. Read More. Read More. Read More.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.